Skip to content
  • Sunday, 26 July 2026
  • 4:30 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Contraline Secures $92.5 Million in Series B Funding to Advance Reversible Male Contraceptive to Late-Stage Clinical Trials
Pharmaceutical R&D

Contraline Secures $92.5 Million in Series B Funding to Advance Reversible Male Contraceptive to Late-Stage Clinical Trials

Teuku Ryan Jun 3, 2026 0

Contraline, a pioneering biotechnology firm backed by Google Ventures, has successfully closed a substantial $92.5 million Series B financing round.…

Read More
Stem Cell & Regenerative Medicine

Cornell University Scientists Develop Breakthrough Reversible Nonhormonal Male Contraceptive Through Targeted Meiotic Disruption

Dwi Wanna May 22, 2026 0

In a significant advancement for reproductive medicine, a team of researchers at Cornell University has announced a major breakthrough in…

Read More
Stem Cell & Regenerative Medicine

Cornell University Researchers Achieve Milestone in Developing Reversible Nonhormonal Male Contraceptive Targeting Meiosis

Dwi Wanna May 14, 2026 0

The pursuit of a reliable, reversible, and nonhormonal male contraceptive has long been described by the medical community as the…

Read More
Stem Cell & Regenerative Medicine

Discovery of Protein Interaction Regulating Sperm Morphogenesis Offers New Insights into Male Infertility and Contraceptive Development

Dwi Wanna May 14, 2026 0

The human biological system relies upon a sophisticated architecture of checks and balances to ensure the precise growth, maturation, and…

Read More
Stem Cell & Regenerative Medicine

Cornell University Scientists Identify Potential Pathway for Reversible Non-Hormonal Male Contraceptive Targeting Meiosis

Dwi Wanna May 7, 2026 0

Researchers at Cornell University have announced a significant breakthrough in reproductive science, successfully demonstrating a method for a safe, reversible,…

Read More
Stem Cell & Regenerative Medicine

Cornell University scientists develop a safe reversible and long-acting nonhormonal male contraceptive through targeted meiotic disruption

Dwi Wanna Apr 30, 2026 0

Researchers at Cornell University have announced a significant breakthrough in reproductive science, successfully demonstrating a method for nonhormonal male contraception…

Read More
Stem Cell & Regenerative Medicine

Cornell University Scientists Develop Safe and Reversible Nonhormonal Male Contraceptive Targeting the Meiosis Process

Dwi Wanna Apr 23, 2026 0

In a milestone for reproductive medicine, researchers at Cornell University have announced a significant breakthrough in the quest for a…

Read More
Stem Cell & Regenerative Medicine

Yale Led Research Uncovers Molecular Mechanism Blocking Fertilization Offering New Paths for Infertility and Contraceptive Science

Dwi Wanna Apr 22, 2026 0

In a landmark study that bridges four decades of biological mystery with cutting-edge structural chemistry, a research team led by…

Read More
Stem Cell & Regenerative Medicine

Yale Research Team Deciphers Molecular Mechanism Blocking Fertilization Paving the Way for New Contraceptive and Infertility Treatments

Dwi Wanna Apr 14, 2026 0

A multidisciplinary research team led by Yale University has successfully mapped the complex biological mechanisms that prevent sperm cells from…

Read More
Stem Cell & Regenerative Medicine

Yale Researchers Uncover Molecular Mechanism Preventing Fertilization Opening New Paths for Infertility and Contraceptive Science

Dwi Wanna Mar 21, 2026 0

In a landmark study that bridges the gap between molecular biophysics and reproductive medicine, a Yale-led research team has successfully…

Read More

Posts pagination

1 2
Quantum Sensing with Diamond Defects Unlocks New Frontier in the Identification of Altermagnetic MaterialsThe Fluid Dynamics of Strength: How Water Flow and Odd Elasticity Define the Limits of Muscle Performance"Just in Time" World Modeling Supports Human Planning and ReasoningRemepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ